(Q38068539)

28 August 2017

1 reference

title

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy (English)

1 reference

28 August 2017

0 references

4

Vincent Haufroid

1 reference

28 August 2017

2

Teun van Gelder

1 reference

28 August 2017

Laure Elens

1

1 reference

28 August 2017

Dennis A Hesselink

series ordinal

3

1 reference

28 August 2017

Ron H N van Schaik

series ordinal

5

1 reference

28 August 2017

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

47-62

1 reference

Pharmacogenetics: from bench to byte--an update of guidelines

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The P450 gene superfamily: recommended nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Significance of the minor cytochrome P450 3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The role of CYP3A4 mRNA transcript with shortened 3'-untranslated region in hepatocyte differentiation, liver development, and response to drug induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Cytochrome P450 3A: ontogeny and drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Increased transcriptional activity of the CYP3A4*1B promoter variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Association of CYP3A4 genotype with treatment-related leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Pharmacogenetic biomarkers: cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4 and CYP3A5 genotyping by Pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Genotypes and phenotypes of CYP3A in Bangladeshi population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A phenotypes and genotypes in North Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4 and MDR1 alleles in a Portuguese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Analysis of CYP3A4 genetic polymorphisms in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Dosing equation for tacrolimus using genetic variants and clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Validation of tacrolimus equation to predict troughs using genetic and clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

In vitro metabolism of cyclosporine A by human kidney CYP3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Factors influencing midazolam hydroxylation activity in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.187

21 January 2018

Identifiers

DOI

10.2217/PGS.12.187

1 reference

28 August 2017

1 reference